REGN7544 clinical trials

A Phase 2 Randomized, Double-Blind, Placebo-Controlled Study to Assess the Efficacy, Safety, Pharmacokinetics, and Pharmacodynamic Effects of REGN7544, an Antagonist Monoclonal Antibody to NPR1, in Patients with Sepsis-Induced Hypotension

This study looks at a new medicine called REGN7544 for people who have very low blood pressure due to a serious infection (sepsis). We want to see if it helps keep blood pressure stable and is safe to use, compared to a dummy medicine.